Table 2.
Results of probabilistic sensitivity analyses
| Variable | Healthcare perspective | Societal perspective |
|---|---|---|
| EVT strategy | ||
| Lifetime effectiveness | 20.32 QALYs | 20.34 QALYs |
| Lifetime costs | $559,212 | $888,782 |
| Lifetime NMB* | $455,029 | $125,627 |
| SC strategy | ||
| Lifetime effectiveness | 16.33 QALYs | 16.32 QALYs |
| Lifetime costs | $729,195 | $1,142,892 |
| Lifetime NMB* | $85,219 | -$326,351 |
| EVT compared to SC strategy | ||
| Incremental effectiveness | 3.99 QALYs | 4.02 QALYs |
| Incremental costs | –$169,982 | –$254,110 |
| Incremental NMB* | $369,810 | $451,978 |
| EVT acceptability at WTP | ||
| $50,000/QALY | 96.08% | 96.61% |
| $100,000/QALY | 96.49% | 96.64% |
| $150,000/QALY | 96.60% | 96.66% |
All values are median values derived from probabilistic sensitivity analyses using 10,000 second order Monte Carlo simulation runs.
EVT, endovascular thrombectomy; QALY, quality-adjusted life year; NMB, net monetary benefit; SC, standard of care; WTP, willingness-to-pay.
*
The WTP threshold was set to $100,000/QALY for all NMB calculations. Negative incremental costs indicate cost-savings and positive incremental NMB values represent higher net monetary benefits associated with EVT.